June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

July 19, 2016July 19, 2016

Researchers Identify How Melanoma Avoids Immune Checkpoints, Potentially Leading to New Therapies

News

Researcher at the University of California, Los Angeles (UCLA) have identified new mechanisms used by melanoma cells to avoid being recognized by the immune system and therefore escape it. This ... Read more

July 14, 2016July 14, 2016

Melanoma Gene Expression Testing Changed Clinical Treatment for Over Half the Patients Tested, Study Shows

News

A design impact study of Castle Biosciences‘ DecisionDx-Melanoma gene expression profile (GEP) test for cutaneous melanoma (CM) was recently published in the journal Current Medical Research and Opinion. The test by Texas-based ... Read more

July 12, 2016July 12, 2016

Easier Access to Melanoma Screenings Doesn’t Result in Excessive Treatment, Community Study Reports

News

Results from a large-scale melanoma screening conducted in Pennsylvania indicate that, overall, the practice complies with the medical maxim: “first do no harm.” The numbers show that melanoma screenings did ... Read more

July 7, 2016July 7, 2016

Medical Cannabis Therapy for Melanoma Being Developed at University of Canberra

News

The University of Canberra has signed a $1 million (Australian dollars) collaboration with Cann Pharmaceutical — a joint venture between better Medical Grade Cannabis of Israel and Australia’s Curus Medical — to create a ... Read more

July 5, 2016July 5, 2016

Malignant Melanoma Rates Up 155% Among Older Adults in UK Since 1990s

News

Cancer Research UK released demographic data this week showing that malignant melanoma rates in the U.K. have more than doubled among people ages 55 and older since the mid-1990s, and are also ... Read more

June 30, 2016June 30, 2016

Melanoma Skin Check Partners Help Patients Identify New Cancers

News

A recent clinical trial proved that skin-check partners of melanoma patients can successfully assist with skin self-examinations by recognizing new melanomas and increasing early detection of the cancer. The study, “Early Detection of New Melanomas ... Read more

June 28, 2016June 28, 2016

Melanoma Identified by Cognitive Technology Closer with IBM, Australian Research

News

IBM Research in Australia will conduct new research with Melanoma Institute Australia to help further a plan to use cognitive technology for melanoma identification. The project builds on IBM’s pre-existing agreement with MoleMap – a company that ... Read more

June 23, 2016June 23, 2016

Combination Immunotherapy for Melanoma Receives NICE Approval

News

The National Institute for Health and Care Excellence (NICE) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients in England and Wales with metastatic melanoma. Ipilumumab targets the CTLA-4 molecule found ... Read more

June 16, 2016June 16, 2016

Early Studies Show Ricolinostat Boosts Immunotherapy Used to Treat Melanoma

News

Acetylon Pharmaceuticals announced the publication of two abstracts describing preclinical trials that demonstrated the potential of ricolinostat (ACY-1215), a HDAC6 inhibitor, to augment immunotherapies used to treat melanoma, and plans to start clinical testing in ... Read more

June 14, 2016June 14, 2016

Brake Release in Natural Killer (NK) Cells Could Boost Cancer Defenses

News

While many scientists have focused on how to make adaptive immune T-cells better fight cancer, Drs. Sandra Nicholson and Nicholas Huntington looked to a subtype of innate immune cells specialized in eliminating ... Read more

June 9, 2016June 9, 2016

Radiation, Immunotherapy Combo a Promising Approach Against Melanoma

News

Researchers at Loyola University Chicago Stritch School of Medicine have found that the combination of new immunotherapies with radiation therapy offers a promising therapeutic approach for melanoma patients. The study, “The integration ... Read more

June 7, 2016June 7, 2016

New Uveal Melanoma Clinical Data Revealed at ASCO 2016

News

Castle Biosciences, a manufacturer of molecular diagnostics for cancer treatments, recently revealed current clinical data on a new test designed to predict metastasis in patients with uveal melanoma. The information about ... Read more

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

Researchers Provide New Insights into Melanoma Immune Resistance

New Clinical Trial Underway for Treatment of Advanced Melanoma

Skin Cancer Awareness Month Brings Sun Safety to Schools

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group